CRP and rheumatoid arthritis: This study revealed that treatment with etanercept biosimilar 1 in patients with active RA resulted in clinical assessments, demonstrating improvement at 12 weeks in DAS28-CRP, DAS28-ESR, SDAI, and CDAI scores, with additional improvements observed at 24 weeks.